Figure 8. Treatment with Y27632 causes increased production of lambda protein in vivo.

2 groups of BALB/c nude mice (n=3) and control group were subcutaneously implanted with 5*10⁶ MDA-MB-231 cells. After animals had flank tumors established (> 600 mm³) they were treated with one intratumoral injection of MV-Lambda 2*10⁶ TCID₅₀. Treatment group received Y27632 through intraperitoneal injection twice daily at 10 mg/kg dose for a total of 10 doses. On day 5 blood was obtained from the animals and isolated serum was tested for levels of human lambda levels. Control animals did not have any detectable levels. Levels were reported in ng/mL and p value calculated is shown on the graph.